Dr. Abhijit Saste, MD - Hematologist in ...

Dr. Abhijit B. Saste

Claim this profile

ProMedica Flower Hospital

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
12 reported clinical trials
28 drugs studied

Area of expertise

1

Lung Cancer

Abhijit B. Saste has run 6 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage I
2

Non-Small Cell Lung Cancer

Abhijit B. Saste has run 5 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage III

Affiliated Hospitals

Image of trial facility.

ProMedica Flower Hospital

Image of trial facility.

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital

Clinical Trials Abhijit B. Saste is currently running

Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Recruiting

1 award

Phase 2 & 3

13 criteria

Image of trial facility.

Venetoclax + Obinutuzumab

for Leukemia

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.

Recruiting

2 awards

Phase 3

1 criteria

More about Abhijit B. Saste

Clinical Trial Related

6 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Abhijit B. Saste has experience with

  • Carboplatin
  • Cisplatin
  • Biospecimen Collection
  • Talazoparib
  • Avelumab
  • Crizotinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Abhijit B. Saste specialize in?

Is Abhijit B. Saste currently recruiting for clinical trials?

Are there any treatments that Abhijit B. Saste has studied deeply?

What is the best way to schedule an appointment with Abhijit B. Saste?

What is the office address of Abhijit B. Saste?

Is there any support for travel costs?